Is Novartis AG (NVS) a Good Buy in the Drug Manufacturers

Novartis AG (NVS) is around the top of the Drug Manufacturers - General industry according to InvestorsObserver. NVS received an overall rating of 42, which means that it scores higher than 42 percent of all stocks. Novartis AG also achieved a score of 67 in the Drug Manufacturers - General industry, putting it above 67 percent of Drug Manufacturers - General stocks. Drug Manufacturers - General is ranked 85 out of the 148 industries.

NVS has an Overall Score of 42. Find out what this means to you and get the rest of the rankings on NVS!

See Full NVS Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Novartis AG Stock Today?

Novartis AG (NVS) stock is lower by -0.74% while the S&P 500 is higher by 0.04% as of 1:10 PM on Friday, Sep 24. NVS has fallen -$0.62 from the previous closing price of $83.57 on volume of 1,098,981 shares. Over the past year the S&P 500 has gained 37.09% while NVS has fallen -3.88%. NVS earned $3.96 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 20.96. Click Here to get the full Stock Report for Novartis AG stock.